

Q Fever

DATIENT DEMOCRAPHICS	
PATIENT DEMOGRAPHICS	
Name (last, first):	Birth date:// Age:
Address (mailing):	
Address (physical):	
City/State/Zip:	☐Hispanic or Latino ☐Unk
Phone (home): Phone (work/cell	l): Race: \(\Black/Afr. Amer.
Alternate contact: □Parent/Guardian □Spouse □Other	(Mark all □Asian □Am. Ind/AK Native
Name:P	Phone: that apply)
INVESTIGATION SUMMARY	
Local Health Department (Jurisdiction):	Entered in WVEDSS? □Yes □No □Unk
Investigation Start Date: / /	Case Classification:
Earliest date reported to LHD://	☐ Confirmed ☐ Probable ☐ Suspect
Earliest date reported to DIDE://	□ Not a case □ Unknown
REPORT SOURCE/HEALTHCARE PROVIDER (HCP)	
Report Source: □Laboratory □Hospital □HCP □Public Health Age	ancy DOthor
Reporter Name: Primary HCP Name:	Primary HCP Phone:
CLINICAL	FIIIIdiy HCF FIIOHE
	Nata: / / Pacayary data: / /
	date:/ Recovery date: /_/
Clinical Findings	Clinical Findings (continued)
YNU ☐ ☐ Fever (Highestmeasured temperature:°F)	YNU YNU YNU YNU Cough
□ □ Rigors	□□□ Myalgia □□□ Splenomegaly □□□ Hepatomegaly
□ □ □ Headache	Clinical Risk Factors
□ □ □ Retrobulbar pain	YNU
□ □ □ Acute hepatitis	□ □ □ Immunocompromised
□ □ □ Pneumonia (CXR confirmed: □ Yes □ No)	□□□ Valvular heart disease or vascular graft
□ □ □ Culture-negative endocarditis	
□ □ □ Suspected infection of a vascular aneurysm	Hospitalization
□ □ □ Suspected infection of a vascular prosthesis	YNU
□ □ □ Chronic hepatitis	□ □ □ Patient hospitalized for this illness
□ □ □ Chronic osteomyelitis	If yes, hospital name:
□ □ □ Chronic osteoarthritis	If yes, hospital name: Admit date:// Discharge date: _//
□ □ □ Chronic pneumonitis	Death
☐ ☐ ☐ Absence of other known etiology	YNU
□ □ □ Diagnosed as Q fever (specify: □ Acute □ Chronic)	□□□ Patient died due to this illness If yes, date of death: / /
VACCINATION HISTORY	TREATMENT
YNU	YNU
☐ ☐ Previously received Q fever vaccine	□ □ Patient received antibiotic therapy for this infection
If yes, date: / /	If yes, type:Duration:
LABORATORY (Please submit copies of <u>all</u> labs, including metabo	olic panels associated with this illness to DIDE)
YNU	
☐ ☐ ☐ Elevated liver enzymes ☐ ☐ ☐ Fourfold change in IgG-specific antibody titer to <i>C. burnetii</i> phase II antigen by IFA between paired serum specimens	
□ □ □Detection of <i>C. burnetii</i> DNA in a clinical specimen via amplification of a specific target by PCR assay	
□ □ □Demonstration of <i>C. burnetii</i> antigen in a clinical specimen by immunohistochemical (IHC) methods	
☐ ☐ ☐ Isolation of <i>C. burnetii</i> from a clinical specimen by culture	
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐	
☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐	
□ □ Serological evidence of IgG antibody to <i>C. burnetii</i> phase I antigen ≥ 1:800 by IFA	
□ □ □ C. burnetii phase I titer > C. burnetii phase II titer	
□ □ □ Antibody titer to <i>C. burnetii</i> phase I IgG antigen ≥1:128 and < 1:800 by IFA	

INFECTION TIMELINE Exposure period Onset date Instructions: Enter onset date in grey box. Count -3 -30 backward to determine (Max Incubation) (Min Incubation) probable exposure period Calendar dates: EPIDEMIOLOGIC EXPOSURES (based on the above exposure period, unless otherwise noted) ☐ ☐ History of travel during exposure period up to **one year** (if yes, complete travel history below): **Destination (City, County, State and Country) Arrival Date** Departure Date Reason for Travel □ □ Possible occupational exposure (indicate occupation at date of illness onset below): ☐Wool or felt plant □Tannery or rendering plant □ Dairy □Animal research □Veterinarian □ Laboratory worker □Slaughterhouse worker □Rancher ☐Medical research □Lives with a person who works in any of the specified occupations □Other occupation: ☐ ☐ ☐ Contact with animals in **2 months** prior to illness onset If yes, specify: □Cattle □Sheep □Goats □Pigeons □Cats □Rabbits □Other: □ □ □ Contact with birthing animals Location: ____ If yes, specify: Animal: ☐ ☐ ☐ Consumption of unpasteurized milk _Date: __/__/___ Location: If yes, specify: Animal:_____ ☐ ☐ ☐ Family members ill with similar illness in past **year** □ □ □ Organ or tissue transplant recipient If yes, date: /_/__ □ □ □ Blood transfusion or blood products recipient If yes, date: / / Where did exposure most likely occur? County:_____ State: Country: _ **PUBLIC HEALTH ISSUES PUBLIC HEALTH ACTIONS** □ □ □ Case donated blood products, organs or tissue □ □ □ Notify blood or tissue bank or other facility where organs donated in the 30 days prior to symptom onset □ □ □ Notify patient obstetrician Date: / / □ □ Disease education and prevention information provided to patient Agency/location: and/or family/guardian Type of donation: □ □ □ Outreach provided to employer to reduce employee risk □ □ Case is pregnant (Due date: / / □ □ □ Facilitate laboratory testing of other symptomatic persons who have ☐ ☐ ☐ Case knows someone who had shared exposure and is a shared exposure □ □ □ Patient is lost to follow-up currently having similar symptoms ☐ ☐ ☐ Epi link to another confirmed case of same condition □ □ □ Other: \square \square Case is part of an outbreak □ □ □ Other: **WVEDSS** YNU □ □ Entered into WVEDSS (Entry date: __ / __ /__ Case Status: ☐ Confirmed ☐ Probable ☐ Suspect ☐ Not a case ☐ Unknown **NOTES**